nL-TARD-001
Phase 2Small molecule
nL-TARD-001 is one of 15 small molecule programs targeting ALS. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
14
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
17 competitors in ALS
#DrugCompanyPhaseTrials
1Evrysdi
RocheApproved
Spinraza
BiogenApproved
Tirosint
IInstitut Jerome Lejeune
Approved
Revia
TevaPhase 2
Enablex
AbbViePhase 2
Ranexa
MMenarini International Operations Luxembourg SA
Phase 2
Iglarlixi
SanofiPhase 3
Salbutamol
GSKPhase 2
Buspirone Hydrochloride
TevaPhase 3
Balstilimab
AAgenus Inc.
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for nL-TARD-001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- Nn-Lorem Foundation